乳腺癌的分子靶向治疗  

Molecular Targeted Therapyfor Breast Cancer

作　　者：赵明[1] 洪祝平 王大巾[1] 郭江峰[1] 丁先锋[1] 孟旭丽[2] 

机构地区：[1]浙江理工大学生命科学学院,杭州市310018 [2]浙江省立同德医院,杭州市310012

出　　处：《医学分子生物学杂志》2015年第5期301-305,共5页Journal of Medical Molecular Biology

基　　金：浙江省科技计划项目（No.2014C03004）,浙江省自然科学基金（No.LY15C050002,LY13H160029）

摘　　要：分子靶向治疗指使用单克隆抗体、多肽等物质特异性干预调节肿瘤细胞生物学行为的信号通路，从而达到抑制肿瘤生长的目的。临床实践证明分子靶向治疗对乳腺肿瘤治疗已经取得显著的疗效作用。从乳腺癌治疗的相关靶点及靶向药物治疗的研究进展进行综述，包括针对人类表皮生长因子受体-2（HER-2）、表皮生长因子受体（EGFR）、血管内皮生长因子（VEGF）和针对多靶点的靶向药物及其作用机制，最后介绍了临床发现治疗乳腺癌的联合用药和用药过后产生的耐药机制研究进展。Molecular targeted therapy utilizes monoclonal antibody and polypeptide, etc. , to specifically target the key signal pathways involved in the regulation of the malignant behaviors of tumor cells to inhibit the tumor growth. It has achieved a remarkable clinical efficacy in the treatment of breast cancer. This article reviews the related treatment targets for breast cancer, the advances on targeted drugs, like those against human epidermal growth factor receptor-2 （HER-2）, epidermal growth factor receptor （EGFR）, vascular endothelial growth factor （VEGF） and those focusing on multiple targets, and the action mechanism. The combination of drugs for the treatment of breast cancer and drug-resistant mechanisms are elucidated as well.

关 键 词：乳腺癌 HER-2受体 分子靶向治疗 联合用药 

分 类 号：R737.9[医药卫生—肿瘤]